<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="case-report" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="pmc-domain-id">2757</journal-id><journal-id journal-id-type="pmc-domain">cureus</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12849829</article-id><article-id pub-id-type="pmcid-ver">PMC12849829.1</article-id><article-id pub-id-type="pmcaid">12849829</article-id><article-id pub-id-type="pmcaiid">12849829</article-id><article-id pub-id-type="pmid">41613724</article-id><article-id pub-id-type="doi">10.7759/cureus.100325</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Internal Medicine</subject></subj-group><subj-group><subject>Rheumatology</subject></subj-group><subj-group><subject>Nephrology</subject></subj-group></article-categories><title-group><article-title>Primary Sj&#246;gren&#8217;s Syndrome Presenting With Severe Hypokalemia Due to Distal Renal Tubular Acidosis: A Case Report</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Muacevic</surname><given-names initials="A">Alexander</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Adler</surname><given-names initials="JR">John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Nguyen</surname><given-names initials="NQ">Ngoc Quy</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dang</surname><given-names initials="DA">Dao A</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Le</surname><given-names initials="TT">Tien T</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Le</surname><given-names initials="TT">The T</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Nguyen</surname><given-names initials="SV">Son V</given-names></name><xref rid="aff-2" ref-type="aff">2</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Department of Nephrology and Endocrinology, Da Nang Hospital, Da Nang, VNM </aff><aff id="aff-2">
<label>2</label>
Department of Stroke, Da Nang Hospital, Da Nang, VNM </aff><author-notes><corresp id="cor1">
Son V. Nguyen <email>dangsonnguyen1892@gmail.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>12</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2025</year></pub-date><volume>17</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">501569</issue-id><elocation-id>e100325</elocation-id><history><date date-type="accepted"><day>29</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>29</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-30 09:25:14.423"><day>30</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025, Nguyen et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nguyen et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cureus-0017-00000100325.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cureus.com/articles/392754-primary-sjgrens-syndrome-presenting-with-severe-hypokalemia-due-to-distal-renal-tubular-acidosis-a-case-report">This article is available from https://cureus.com/articles/392754-primary-sjgrens-syndrome-presenting-with-severe-hypokalemia-due-to-distal-renal-tubular-acidosis-a-case-report</self-uri><abstract><p>Primary Sj&#246;gren&#8217;s syndrome is a systemic autoimmune disorder with diverse clinical manifestations. Although exocrine gland dysfunction is the hallmark, renal involvement, particularly distal renal tubular acidosis (type 1 RTA), can occur and may precede classic sicca symptoms. We report a case of a 55-year-old woman presenting with acute lower limb weakness due to severe hypokalemia. Laboratory investigations revealed normal anion gap metabolic acidosis with inappropriately alkaline urine, consistent with type 1 RTA. Further evaluation uncovered subtle sicca symptoms, parotid gland enlargement, and serologic positivity for anti-Ro/SSA and anti-La/SSB antibodies, supporting the diagnosis of primary Sj&#246;gren&#8217;s syndrome. The patient responded well to potassium and bicarbonate supplementation. This case underscores the importance of considering autoimmune etiologies such as primary Sj&#246;gren&#8217;s syndrome in patients with unexplained hypokalemia and tubular acidosis, even in the absence of overt sicca features.</p></abstract><kwd-group kwd-group-type="author"><kwd>autoimmune disease</kwd><kwd>distal renal tubular acidosis</kwd><kwd>electrolyte imbalance</kwd><kwd>hypokalemia</kwd><kwd>renal involvement</kwd><kwd>sj&#246;gren&#8217;s syndrome</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Sj&#246;gren&#8217;s syndrome is an autoimmune disorder characterized by lymphocytic infiltration of exocrine glands, resulting in sicca symptoms and a wide range of systemic manifestations. It can occur as a primary disorder or secondary to other autoimmune diseases [<xref rid="REF1" ref-type="bibr">1</xref>]. Most patients exhibit impaired exocrine gland function, leading to symptoms such as dry eyes and dry mouth, which may cause difficulty swallowing and an increased risk of dental caries. Physical examination may reveal non-tender parotid gland enlargement. Approximately 30% to 40% of patients present with systemic manifestations, and renal involvement occurs in about 5% of cases [<xref rid="REF2" ref-type="bibr">2</xref>]. The pathophysiological mechanisms linking Sj&#246;gren&#8217;s syndrome to distal renal tubular acidosis (RTA) remain incompletely understood. Proposed mechanisms include loss of H&#8314;-ATPase expression in renal tubular cells and the presence of autoantibodies against carbonic anhydrase II in patients with primary Sj&#246;gren&#8217;s syndrome. In this report, we present a case of suspected primary Sj&#246;gren&#8217;s syndrome initially manifesting as hypokalemia due to a renal tubular defect. This case highlights the clinical heterogeneity of Sj&#246;gren&#8217;s syndrome and the importance of a systematic approach to hypokalemia, a common electrolyte disturbance in clinical practice.</p></sec><sec sec-type="cases"><title>Case presentation</title><p>A 55-year-old female patient with a history of bile duct stones treated via endoscopic retrograde cholangiopancreatography, no prior head and neck irradiation, and a prior episode of mild hypokalemia managed with oral potassium supplementation presented with acute lower limb weakness. One day prior to admission, she noticed progressive weakness in both legs. She self-medicated with an unknown drug, and by the morning of admission, the weakness had acutely worsened and spread to the upper limbs and lower back, prompting her admission to the ICU.&#160;At the ICU, she was found to have severe hypokalemia (1.66 mmol/L) and received intravenous potassium supplementation. Once stabilized, she was transferred to the nephrology ward for further evaluation.</p><p>On examination at the nephrology unit, the patient was alert and oriented, with no edema or paresthesia. Muscle strength was 5/5 throughout. She denied nausea, headache, or focal neurologic signs. Her pulse was 78 beats per minute (bpm), and her blood pressure was 130/80 mmHg. She was 155 cm tall and weighed 58 kg, with a corresponding BMI of 24.2 kg/m&#178;.&#160;The patient reported a normal diet, with no dietary restrictions. Further history-taking revealed symptoms suggestive of sicca syndrome, including eye dryness when exposed to wind and difficulty swallowing dry foods. On examination, the right parotid gland was non-tender and enlarged.</p><p>Initial laboratory findings showed a serum potassium level as low as 1.66 mmol/L. Arterial blood gas analysis revealed normal anion gap metabolic acidosis (bicarbonate (HCO&#8323;&#8315;) 15.4 mmol/L, pH 7.235, pCO&#8322; 37.3 mmHg), serum sodium 149.1 mmol/L, and serum chloride 118 mmol/L. Urinalysis showed alkaline urine (pH 8.0) with low specific gravity (1.006). Urinary electrolytes revealed sodium levels of 73.7 mmol/L, potassium of 11.96 mmol/L, and chloride of 76 mmol/L&#160;(Table <xref rid="TAB1" ref-type="table">1</xref>). Based on the laboratory findings, the urinary potassium-to-creatinine ratio =&#160;15.53 mmol/mmol, the serum anion gap = 15.7, and the urine anion gap = 9.66 can be readily calculated.&#160;These findings led to a diagnosis of distal RTA (type 1 RTA). Ultrasound examination of the patient&#8217;s parotid glands revealed no abnormalities (Figure <xref rid="FIG1" ref-type="fig">1</xref>). Bone mineral density assessment by dual-energy X-ray absorptiometry (DEXA) scan indicated osteopenia, with T-scores of -1.1 at the femoral neck and -1.8 at the lumbar spine (Figure <xref rid="FIG2" ref-type="fig">2</xref> and Table <xref rid="TAB2" ref-type="table">2</xref>).</p><table-wrap position="float" id="TAB1" orientation="portrait"><label>Table 1</label><caption><title>Laboratory results</title><p>HCO<sub>3</sub>-: bicarbonate; HCV: hepatitis C virus; ELISA:&#160;enzyme-linked Immunosorbent assay</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Lab</td><td rowspan="1" colspan="1">Value</td><td rowspan="1" colspan="1">Reference range</td></tr><tr><td colspan="3" rowspan="1">Serum</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sodium (mmol/L)</td><td rowspan="1" colspan="1">149.1</td><td rowspan="1" colspan="1">135 &#8211; 145</td></tr><tr><td rowspan="1" colspan="1">Potassium (mmol/L)</td><td rowspan="1" colspan="1">1.66</td><td rowspan="1" colspan="1">3.5 &#8211; 5.0</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Chloride (mmol/L)</td><td rowspan="1" colspan="1">118</td><td rowspan="1" colspan="1">96 &#8211; 110</td></tr><tr><td rowspan="1" colspan="1">HCO3- (mmol/L)</td><td rowspan="1" colspan="1">15.4</td><td rowspan="1" colspan="1">21 &#8211; 26</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">pH</td><td rowspan="1" colspan="1">7.235</td><td rowspan="1" colspan="1">7.35 &#8211; 7.45</td></tr><tr><td rowspan="1" colspan="1">pCO<sub>2</sub> (mmHg)</td><td rowspan="1" colspan="1">37.3</td><td rowspan="1" colspan="1">35 &#8211; 45</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Creatinin (&#181;mol/L)</td><td rowspan="1" colspan="1">80.9</td><td rowspan="1" colspan="1">Male: 62 &#8211; 106; Female: 44 - 80</td></tr><tr><td colspan="3" rowspan="1">Urine</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">pH</td><td rowspan="1" colspan="1">8.0</td><td rowspan="1" colspan="1">4.8 -7.4</td></tr><tr><td rowspan="1" colspan="1">Specific gravity</td><td rowspan="1" colspan="1">1.006</td><td rowspan="1" colspan="1">1.015 &#8211; 1.025</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sodium (mmol/L)</td><td rowspan="1" colspan="1">73.7</td><td rowspan="1" colspan="1">40 &#8211; 220</td></tr><tr><td rowspan="1" colspan="1">Potassium (mmol/L)</td><td rowspan="1" colspan="1">11.96</td><td rowspan="1" colspan="1">25 &#8211; 125</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Chloride (mmol/L)</td><td rowspan="1" colspan="1">76</td><td rowspan="1" colspan="1">110 &#8211; 250</td></tr><tr><td rowspan="1" colspan="1">Creatinine &#181;mol/L</td><td rowspan="1" colspan="1">770,9</td><td rowspan="1" colspan="1">&#160;</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Protein (g/24h)</td><td rowspan="1" colspan="1">0.0744</td><td rowspan="1" colspan="1">&lt; 0.15</td></tr><tr><td colspan="3" rowspan="1">Immunologic workup</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Anti&#8211;HCV</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">Anti-HIV</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">C3 (mg/dL)</td><td rowspan="1" colspan="1">127</td><td rowspan="1" colspan="1">90 &#8211; 180</td></tr><tr><td rowspan="1" colspan="1">C4 (mg/dL)</td><td rowspan="1" colspan="1">12.8</td><td rowspan="1" colspan="1">10 &#8211; 40</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Direct Coombs test</td><td rowspan="1" colspan="1">Posivite</td><td rowspan="1" colspan="1">Negative</td></tr><tr><td rowspan="1" colspan="1">Indirect Coombs test</td><td rowspan="1" colspan="1">Positive</td><td rowspan="1" colspan="1">Negative</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">ANA (ELISA)</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">&lt; 0.9: Negative; 0.9 &#8211; 1.1: gray zone; &gt; 1.1: Positive</td></tr><tr><td rowspan="1" colspan="1">Anti&#8211;DSDNA</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">Negavite: 0 &#8211; 5; Borderline: 6 &#8211; 10; Positive: 11 &#8211; 25, 26 &#8211; 50; Strong positive: &gt; 50</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Anti&#8211;SSA</td><td rowspan="1" colspan="1">Positive (49)</td><td rowspan="1" colspan="1">Negavite: 0 &#8211; 5; Borderline: 6 &#8211; 10; Positive: 11 &#8211; 25, 26 &#8211; 50; Strong positive: &gt; 50</td></tr><tr><td rowspan="1" colspan="1">Anti&#8211;Ro 52</td><td rowspan="1" colspan="1">Strong positive (83)</td><td rowspan="1" colspan="1">Negavite: 0 &#8211; 5; Borderline: 6 &#8211; 10; Positive: 11 &#8211; 25, 26 &#8211; 50; Strong positive: &gt; 50</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Anti&#8211;SSB</td><td rowspan="1" colspan="1">Strong positive (67)</td><td rowspan="1" colspan="1">Negavite: 0 &#8211; 5; Borderline: 6 &#8211; 10; Positive: 11 &#8211; 25, 26 &#8211; 50; Strong positive: &gt; 50</td></tr><tr><td rowspan="1" colspan="1">Anti&#8211;RNP</td><td rowspan="1" colspan="1">Positive (20)</td><td rowspan="1" colspan="1">Negavite: 0 &#8211; 5; Borderline: 6 &#8211; 10; Positive: 11 &#8211; 25, 26 &#8211; 50; Strong positive: &gt; 50</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Anti&#8211;Sm</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">Negavite: 0 &#8211; 5; Borderline: 6 &#8211; 10; Positive: 11 &#8211; 25, 26 &#8211; 50; Strong positive: &gt; 50</td></tr><tr><td rowspan="1" colspan="1">Anti&#8211;Scl&#8211;70</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">Negavite: 0 &#8211; 5; Borderline: 6 &#8211; 10; Positive: 11 &#8211; 25, 26 &#8211; 50; Strong positive: &gt; 50</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Anti-Jo-1</td><td rowspan="1" colspan="1">Negative</td><td rowspan="1" colspan="1">Negavite: 0 &#8211; 5; Borderline: 6 &#8211; 10; Positive: 11 &#8211; 25, 26 &#8211; 50; Strong positive: &gt; 50</td></tr><tr><td rowspan="1" colspan="1">Rheumatoid factor (IU/mL)</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">&lt; 8</td></tr></tbody></table></table-wrap><fig position="anchor" fig-type="figure" id="FIG1" orientation="portrait"><label>Figure 1</label><caption><title>Ultrasonography of the right parotid gland </title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000100325-i01.jpg"/></fig><fig position="anchor" fig-type="figure" id="FIG2" orientation="portrait"><label>Figure 2</label><caption><title>Bone mineral density result</title></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000100325-i02.jpg"/></fig><table-wrap position="float" id="TAB2" orientation="portrait"><label>Table 2</label><caption><title>Densitomety data</title><p>N/C:&#160;not calculated</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Region of interest</td><td rowspan="1" colspan="1">Bone mineral density (g/cm<sup>2</sup>)</td><td rowspan="1" colspan="1">Bone mineral content(g)</td><td rowspan="1" colspan="1">Area (cm<sup>2</sup>)</td><td rowspan="1" colspan="1">T &#8211; Score</td><td rowspan="1" colspan="1">Z &#8211; Score</td></tr><tr><td colspan="6" rowspan="1">Left femur</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Neck</td><td rowspan="1" colspan="1">0.761</td><td rowspan="1" colspan="1">2.21</td><td rowspan="1" colspan="1">2.90</td><td rowspan="1" colspan="1">- 0.5 (94%)</td><td rowspan="1" colspan="1">0.6 (109%)</td></tr><tr><td rowspan="1" colspan="1">
Greater trochanter
</td><td rowspan="1" colspan="1">0.739</td><td rowspan="1" colspan="1">0.25</td><td rowspan="1" colspan="1">0.34</td><td rowspan="1" colspan="1">0.7 (110%)</td><td rowspan="1" colspan="1">1.4 (122%)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">
Intertrochanteric region
</td><td rowspan="1" colspan="1">0.883</td><td rowspan="1" colspan="1">18.98</td><td rowspan="1" colspan="1">21.49</td><td rowspan="1" colspan="1">- 1.1 (84%)</td><td rowspan="1" colspan="1">- 0.7 (90%)</td></tr><tr><td rowspan="1" colspan="1">Total hip</td><td rowspan="1" colspan="1">0.867</td><td rowspan="1" colspan="1">21.44</td><td rowspan="1" colspan="1">24.74</td><td rowspan="1" colspan="1">- 1.1 (85%)</td><td rowspan="1" colspan="1">- 0.6 (92%)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Ward</td><td rowspan="1" colspan="1">0.876</td><td rowspan="1" colspan="1">0.65</td><td rowspan="1" colspan="1">0.74</td><td rowspan="1" colspan="1">N/C</td><td rowspan="1" colspan="1">N/C</td></tr><tr><td colspan="6" rowspan="1">Spine</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">L1</td><td rowspan="1" colspan="1">0.622</td><td rowspan="1" colspan="1">7.53</td><td rowspan="1" colspan="1">12.10</td><td rowspan="1" colspan="1">- 2.4 (71%)</td><td rowspan="1" colspan="1">- 1.4 (81%)</td></tr><tr><td rowspan="1" colspan="1">L2</td><td rowspan="1" colspan="1">0.748</td><td rowspan="1" colspan="1">10.16</td><td rowspan="1" colspan="1">13.59</td><td rowspan="1" colspan="1">- 1.9 (79%)</td><td rowspan="1" colspan="1">- 0.8 (89%)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">L3</td><td rowspan="1" colspan="1">0.832</td><td rowspan="1" colspan="1">13.20</td><td rowspan="1" colspan="1">15.87</td><td rowspan="1" colspan="1">- 1.6 (83%)</td><td rowspan="1" colspan="1">- 0.5 (94%)</td></tr><tr><td rowspan="1" colspan="1">L4</td><td rowspan="1" colspan="1">0.904</td><td rowspan="1" colspan="1">13.93</td><td rowspan="1" colspan="1">15.41</td><td rowspan="1" colspan="1">- 1.3 (87%)</td><td rowspan="1" colspan="1">- 0.2 (98%)</td></tr><tr style="background-color:#ccc"><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">0.787</td><td rowspan="1" colspan="1">44.82</td><td rowspan="1" colspan="1">56.98</td><td rowspan="1" colspan="1">- 1.8 (81%)</td><td rowspan="1" colspan="1">- 0.7 (92%)</td></tr></tbody></table></table-wrap><p>&#8203;&#8203;&#8203;The presence of anti-Ro/SSA and anti-La/SSB antibodies, along with sicca symptoms and parotid gland enlargement, was highly suggestive of primary Sj&#246;gren&#8217;s syndrome.&#160;However, because objective diagnostic tests such as salivary flow measurement, Schirmer&#8217;s test, and salivary gland biopsy could not be performed, the patient was classified as presumed primary Sj&#246;gren&#8217;s syndrome rather than receiving a definitive diagnosis.</p><p>Although the patient exhibited symptoms of dry eyes and mouth, she did not feel the need for further intervention. She had no other systemic manifestations aside from renal tubular abnormalities. Therefore, the patient was treated&#160;with oral potassium chloride and sodium bicarbonate (1 mmol/kg/day), along with oral calcium carbonate supplementation. Ten days later, her clinical condition was stable and serum potassium had normalized (3.95 mmol/L).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Hypokalemia, defined as a serum potassium concentration &lt; 3.5 mmol/L, has a variable prevalence, approximately 2.7% in the general population [<xref rid="REF3" ref-type="bibr">3</xref>] and up to 12% among hospitalized patients [<xref rid="REF4" ref-type="bibr">4</xref>]. The prevalence may be as high as 56% in patients with primary hyperaldosteronism [<xref rid="REF5" ref-type="bibr">5</xref>]. Severe hypokalemia (&lt; 2.5 mmol/L) can lead to symptoms such as palpitations, muscle weakness, and even paralysis. Even asymptomatic mild hypokalemia is associated with increased risk of cardiovascular events and all-cause mortality [<xref rid="REF6" ref-type="bibr">6</xref>].</p><p>Etiologies of hypokalemia are typically categorized into (1) decreased intake, (2) intracellular shift, and (3) increased loss (renal or extrarenal). Various diagnostic approaches have been proposed to evaluate hypokalemia. Among them, the Kidney Disease: Improving Global Outcomes (KDIGO) algorithm offers a practical, structured framework for identifying the underlying cause&#160;(Figure <xref rid="FIG3" ref-type="fig">3</xref>) [<xref rid="REF7" ref-type="bibr">7</xref>]. Applying this approach allowed for the identification of distal RTA (type 1 RTA) as the cause of hypokalemia in our patient.</p><fig position="anchor" fig-type="figure" id="FIG3" orientation="portrait"><label>Figure 3</label><caption><title>Pratical approach to hypokalemia</title><p>HPP: hypokalemic periodic paralysis; Na+: sodium ion; K+: pottassium ion; Cl: chloride; RTA: renal tubular acidosis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cureus-0017-00000100325-i03.jpg"/></fig><p>Metabolic acidosis can result from increased acid production, bicarbonate loss, or impaired acid excretion due to renal dysfunction. Chronic metabolic acidosis can lead to complications such as muscle wasting, decreased bone density, and progression of chronic kidney disease (CKD) [<xref rid="REF8" ref-type="bibr">8</xref>]. Acidosis is classified into two main types based on the anion gap: (1) high anion gap and (2) normal anion gap metabolic acidosis. The latter may be due to extrarenal causes (most commonly chronic diarrhea) or renal causes (i.e., renal tubular acidosis) [<xref rid="REF9" ref-type="bibr">9</xref>]. Differentiation is based on the renal response to acidosis. While direct measurement of urinary ammonium excretion is ideal, it is not widely available. Instead, urinary anion gap or urine osmolal gap can be used as surrogate markers [<xref rid="REF10" ref-type="bibr">10</xref>]. In our patient, an alkaline urine pH of 8 and low serum potassium during metabolic acidosis were consistent with type 1 RTA, a defect in distal nephron proton excretion [<xref rid="REF9" ref-type="bibr">9</xref>]. Classic features include hypokalemia, normal anion gap metabolic acidosis, and persistently high urine pH (&gt;5.5). Associated findings include hypercalciuria and hypocitraturia, predisposing to nephrolithiasis and bone disease. Etiologies include genetic and acquired causes, with Sj&#246;gren&#8217;s syndrome being the most common acquired cause [<xref rid="REF9" ref-type="bibr">9</xref>].</p><p>Upon confirming the diagnosis of type 1 RTA, additional evaluation suggested underlying primary Sj&#246;gren&#8217;s syndrome. As previously noted, primary Sj&#246;gren&#8217;s is a prototypical autoimmune disease with highly variable presentations. It predominantly affects women, with most cases diagnosed around the age of 50 [<xref rid="REF11" ref-type="bibr">11</xref>]. The classic sicca syndrome involves dryness of the eyes and mouth. Diagnosis requires a combination of clinical evaluation (Schirmer&#8217;s test, salivary flow measurement), serologic testing (ANA, RF, anti-Ro, anti-La), and sometimes minor salivary gland biopsy [<xref rid="REF2" ref-type="bibr">2</xref>]. The 2016 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for primary Sj&#246;gren&#8217;s syndrome [<xref rid="REF12" ref-type="bibr">12</xref>] provide a standardized diagnostic framework. Although our patient did not meet full classification criteria, the presence of anti-Ro/SSA and anti-La/SSB antibodies, along with sicca symptoms and parotid gland enlargement, strongly supported the diagnosis. The disease generally follows a slow, benign course but can be associated with complications such as lymphoma or cardiovascular disease [<xref rid="REF1" ref-type="bibr">1</xref>]. Renal involvement occurs in approximately 5% of cases [<xref rid="REF2" ref-type="bibr">2</xref>], most commonly presenting as tubulointerstitial nephritis. Other possible renal manifestations include type 1 RTA with hypokalemia, Fanconi syndrome, and nephrogenic diabetes insipidus. Primary Sj&#246;gren&#8217;s syndrome affects the kidney through lymphocytic infiltration of renal tubules or immune complex deposition. Glomerular disease is less common [<xref rid="REF13" ref-type="bibr">13</xref>]. A recent Taiwanese cohort study found that 5.8% of patients with Sj&#246;gren&#8217;s syndrome developed CKD, and 0.22% progressed to end-stage kidney disease (ESKD). Patients with Sj&#246;gren&#8217;s had a 49% increased risk of CKD compared to the general population, although the risk of ESKD was not significantly elevated (adjusted hazard ratio (HR) 0.82, 95% CI 0.58-1.16) [<xref rid="REF14" ref-type="bibr">14</xref>].</p><p>In a patient such as this, differential diagnoses beyond Sj&#246;gren&#8217;s syndrome include HIV infection and sarcoidosis. Negative HIV serology effectively excludes HIV infection. In addition, the absence of respiratory symptoms makes sarcoidosis less likely. Furthermore, the presence of anti-SSA/SSB antibodies favors Sj&#246;gren&#8217;s syndrome rather than sarcoidosis [<xref rid="REF1" ref-type="bibr">1</xref>]. Another point that warrants discussion in this patient is the positive Coombs test.&#160;Although a positive Coombs test is relatively uncommon in patients with primary Sj&#246;gren&#8217;s syndrome, this finding&#160;can be explained by disease pathogenesis, namely chronic B-cell activation and polyclonal hypergammaglobulinemia, leading to the production of anti-erythrocyte autoantibodies. In addition, a study by R. Ramakrishna has reported cases of Sj&#246;gren&#8217;s syndrome with a positive direct Coombs test [<xref rid="REF15" ref-type="bibr">15</xref>]</p><p>Management is primarily symptomatic: artificial tears, increased fluid intake, and pilocarpine for sicca symptoms. According to the European Alliance of Associations for Rheumatology (EULAR) guidelines for the management of Sj&#246;gren&#8217;s syndrome, renal involvement should be treated based on whether it manifests as tubular or glomerular disease. In cases of tubular involvement, as in this patient, therapeutic decisions are guided by the EULAR Sj&#246;gren&#8217;s Syndrome Disease Activity Index (ESSDAI) category (low, moderate, or high). Patients with a low ESSDAI score require only supportive treatment with sodium bicarbonate and potassium supplementation, whereas glucocorticoids or other immunosuppressive agents, such as mycophenolate mofetil, azathioprine, or cyclophosphamide, may be indicated in those with moderate to high ESSDAI scores [<xref rid="REF16" ref-type="bibr">16</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>This case illustrates the diverse clinical manifestations of primary Sj&#246;gren&#8217;s syndrome, with the initial presentation being lower limb weakness due to severe hypokalemia. A systematic approach to the evaluation of hypokalemia, including acid-base status, urine pH, urinary electrolytes, and anion gap analysis, led to the diagnosis of distal RTA. Careful history-taking, physical examination, and targeted immunologic testing guided the identification of Sj&#246;gren&#8217;s syndrome as the underlying etiology. This case underscores the importance of a structured diagnostic approach to electrolyte disturbances and the need to consider autoimmune causes in unexplained renal tubular dysfunction.</p></sec></body><back><ack><p>Data are available on reasonable request.</p></ack><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Informed consent for treatment and open access publication was obtained or waived by all participants in this study.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>&#160; Ngoc Quy Nguyen, Son V. Nguyen, Dao A. Dang, Tien T. Le, The T. Le</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>&#160; Ngoc Quy Nguyen, Son V. Nguyen, Dao A. Dang, Tien T. Le, The T. Le</p><p><bold>Drafting of the manuscript:</bold>&#160; Ngoc Quy Nguyen, Son V. Nguyen, Tien T. Le, The T. Le</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>&#160; Ngoc Quy Nguyen, Dao A. Dang</p><p><bold>Supervision:</bold>&#160; Dao A. Dang</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="book"><article-title>Sj&#246;gren&#8217;s syndrome</article-title><source>Harrison&#8217;s Principles of Internal Medicine. 21st edition</source><person-group><name name-style="western"><surname>Moutsopoulos</surname><given-names>HM</given-names></name><name name-style="western"><surname>Moutsopoulos</surname><given-names>CP</given-names></name></person-group><fpage>2787</fpage><lpage>2790</lpage><publisher-loc>New York City, NY</publisher-loc><publisher-name>McGraw-Hill Education</publisher-name><year>2022</year></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Primary Sj&#246;gren's syndrome</article-title><source>N Engl J Med</source><person-group><name name-style="western"><surname>Mariette</surname><given-names>X</given-names></name><name name-style="western"><surname>Criswell</surname><given-names>LA</given-names></name></person-group><fpage>931</fpage><lpage>939</lpage><volume>378</volume><year>2018</year><pub-id pub-id-type="pmid">29514034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMcp1702514</pub-id></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Serum potassium, mortality, and kidney outcomes in the Atherosclerosis Risk in Communities study</article-title><source>Mayo Clin Proc</source><person-group><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chang</surname><given-names>AR</given-names></name><name name-style="western"><surname>McAdams DeMarco</surname><given-names>MA</given-names></name><etal/></person-group><fpage>1403</fpage><lpage>1412</lpage><volume>91</volume><year>2016</year><pub-id pub-id-type="pmid">27499535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mayocp.2016.05.018</pub-id><pub-id pub-id-type="pmcid">PMC5531173</pub-id></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Hypokalaemia and subsequent hyperkalaemia in hospitalized patients</article-title><source>Nephrol Dial Transplant</source><person-group><name name-style="western"><surname>Crop</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hoorn</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Lindemans</surname><given-names>J</given-names></name><name name-style="western"><surname>Zietse</surname><given-names>R</given-names></name></person-group><fpage>3471</fpage><lpage>3477</lpage><volume>22</volume><year>2007</year><pub-id pub-id-type="pmid">17848395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfm471</pub-id></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry</article-title><source>J Clin Endocrinol Metab</source><person-group><name name-style="western"><surname>Born-Frontsberg</surname><given-names>E</given-names></name><name name-style="western"><surname>Reincke</surname><given-names>M</given-names></name><name name-style="western"><surname>Rump</surname><given-names>LC</given-names></name><etal/></person-group><fpage>1125</fpage><lpage>1130</lpage><volume>94</volume><year>2009</year><pub-id pub-id-type="pmid">19190103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jc.2008-2116</pub-id></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis</article-title><source>Eur Heart J</source><person-group><name name-style="western"><surname>Kovesdy</surname><given-names>CP</given-names></name><name name-style="western"><surname>Matsushita</surname><given-names>K</given-names></name><name name-style="western"><surname>Sang</surname><given-names>Y</given-names></name><etal/></person-group><fpage>1535</fpage><lpage>1542</lpage><volume>39</volume><year>2018</year><pub-id pub-id-type="pmid">29554312</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehy100</pub-id><pub-id pub-id-type="pmcid">PMC5930249</pub-id></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference</article-title><source>Kidney Int</source><person-group><name name-style="western"><surname>Clase</surname><given-names>CM</given-names></name><name name-style="western"><surname>Carrero</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Ellison</surname><given-names>DH</given-names></name><etal/></person-group><fpage>42</fpage><lpage>61</lpage><volume>97</volume><year>2020</year><pub-id pub-id-type="pmid">31706619</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2019.09.018</pub-id></element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="journal"><article-title>Adverse effects of the metabolic acidosis of chronic kidney disease</article-title><source>Adv Chronic Kidney Dis</source><person-group><name name-style="western"><surname>Kraut</surname><given-names>JA</given-names></name><name name-style="western"><surname>Madias</surname><given-names>NE</given-names></name></person-group><fpage>289</fpage><lpage>297</lpage><volume>24</volume><year>2017</year><pub-id pub-id-type="pmid">29031355</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ackd.2017.06.005</pub-id></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="book"><article-title>Metabolic acidosis</article-title><source>Comprehensive Clinical Nephrology</source><person-group><name name-style="western"><surname>Palmer</surname><given-names>BF</given-names></name></person-group><fpage>161</fpage><lpage>171</lpage><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Elsevier</publisher-name><year>2024</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://shop.elsevier.com/books/comprehensive-clinical-nephrology/johnson/978-0-323-82592-4">https://shop.elsevier.com/books/comprehensive-clinical-nephrology/johnson/978-0-323-82592-4</uri></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>Non-anion gap metabolic acidosis: a clinical approach to evaluation</article-title><source>Am J Kidney Dis</source><person-group><name name-style="western"><surname>Rastegar</surname><given-names>M</given-names></name><name name-style="western"><surname>Nagami</surname><given-names>GT</given-names></name></person-group><fpage>296</fpage><lpage>301</lpage><volume>69</volume><year>2017</year><pub-id pub-id-type="pmid">28029394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2016.09.013</pub-id></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Epidemiology of primary Sj&#246;gren's syndrome: a systematic review and meta-analysis</article-title><source>Ann Rheum Dis</source><person-group><name name-style="western"><surname>Qin</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N</given-names></name><name name-style="western"><surname>Huang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>R</given-names></name></person-group><fpage>1983</fpage><lpage>1989</lpage><volume>74</volume><year>2015</year><pub-id pub-id-type="pmid">24938285</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/annrheumdis-2014-205375</pub-id></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sj&#246;gren&#8217;s syndrome: a consensus and data-driven methodology involving three international patient cohorts</article-title><source>Arthritis Rheumatol</source><person-group><name name-style="western"><surname>Shiboski</surname><given-names>CH</given-names></name><name name-style="western"><surname>Shiboski</surname><given-names>SC</given-names></name><name name-style="western"><surname>Seror</surname><given-names>R</given-names></name><etal/></person-group><fpage>35</fpage><lpage>45</lpage><volume>69</volume><year>2017</year><pub-id pub-id-type="pmid">27785888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/art.39859</pub-id><pub-id pub-id-type="pmcid">PMC5650478</pub-id></element-citation></ref><ref id="REF13"><label>13</label><element-citation publication-type="journal"><article-title>Renal disease in primary Sj&#246;gren&#8217;s syndrome</article-title><source>Rheumatol Ther</source><person-group><name name-style="western"><surname>Aiyegbusi</surname><given-names>O</given-names></name><name name-style="western"><surname>McGregor</surname><given-names>L</given-names></name><name name-style="western"><surname>McGeoch</surname><given-names>L</given-names></name><name name-style="western"><surname>Kipgen</surname><given-names>D</given-names></name><name name-style="western"><surname>Geddes</surname><given-names>CC</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>KI</given-names></name></person-group><fpage>63</fpage><lpage>80</lpage><volume>8</volume><year>2021</year><pub-id pub-id-type="pmid">33367966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40744-020-00264-x</pub-id><pub-id pub-id-type="pmcid">PMC7991017</pub-id></element-citation></ref><ref id="REF14"><label>14</label><element-citation publication-type="journal"><article-title>Long-term renal prognosis among patients with primary Sj&#246;gren's syndrome and renal involvement: a nationwide matched cohort study</article-title><source>J Autoimmun</source><person-group><name name-style="western"><surname>Lin</surname><given-names>CY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HA</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>LH</given-names></name><name name-style="western"><surname>Su</surname><given-names>YJ</given-names></name></person-group><fpage>102483</fpage><volume>113</volume><year>2020</year><pub-id pub-id-type="pmid">32446704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2020.102483</pub-id></element-citation></ref><ref id="REF15"><label>15</label><element-citation publication-type="journal"><article-title>Haematological manifestations of primary Sj&#246;gren's syndrome: a clinicopathological study</article-title><source>Q J Med</source><person-group><name name-style="western"><surname>Ramakrishna</surname><given-names>R</given-names></name><name name-style="western"><surname>Chaudhuri</surname><given-names>K</given-names></name><name name-style="western"><surname>Sturgess</surname><given-names>A</given-names></name><name name-style="western"><surname>Manoharan</surname><given-names>A</given-names></name></person-group><fpage>547</fpage><lpage>554</lpage><volume>83</volume><year>1992</year><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/1484932/">https://pubmed.ncbi.nlm.nih.gov/1484932/</uri><pub-id pub-id-type="pmid">1484932</pub-id></element-citation></ref><ref id="REF16"><label>16</label><element-citation publication-type="journal"><article-title>British Society for Rheumatology guideline on management of adult and juvenile onset Sj&#246;gren disease</article-title><source>Rheumatology (Oxford)</source><person-group><name name-style="western"><surname>Price</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>S</given-names></name><name name-style="western"><surname>Bombardieri</surname><given-names>M</given-names></name><etal/></person-group><fpage>409</fpage><lpage>439</lpage><volume>64</volume><year>2025</year><pub-id pub-id-type="pmid">38621708</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/rheumatology/keae152</pub-id><pub-id pub-id-type="pmcid">PMC12013823</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>